Global Viral Inactivation Market to reach USD 1236.3 million by 2026

Global Viral Inactivation Market Size Study By Method (Solvent Detergent Method, Pasteurization) By Product (Kits and Reagents, Services, Viral Inactivation Systems and Accessories)by Application (Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products, Vaccines and Therapeutics)by End User and Regional Forecasts 2019-2026
Product Code:  HALDAT_98734927
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Key Trends
1.3.	Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1.	Viral Inactivation Market, by Method, 2016-2026 (USD Billion)
1.3.2.	Viral Inactivation Market, by Product, 2016-2026 (USD Billion)
1.3.3.	Viral Inactivation Market, by Application, 2016-2026 (USD Billion)
1.3.4.	Viral Inactivation Market, by End-use, 2016-2026 (USD Billion)
1.3.5.	Viral Inactivation Market, by Region, 2016-2026 (USD Billion)
1.4.	Estimation Methodology
1.5.	Research Assumption 
Chapter 2.	Global Viral Inactivation Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Industry Evolution
2.2.2.	Scope of the Study
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Viral Inactivation Market Dynamics	
3.1.	See Saw Analysis
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Viral Inactivation Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Buyers
4.1.2.	Bargaining Power of Suppliers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model
4.2.	PEST Analysis
4.2.1.	Political Scenario
4.2.2.	Economic Scenario
4.2.3.	Social Scenario
4.2.4.	Technological Scenario
4.3.	Key Buying Criteria (On Demand)
4.4.	Regulatory Framework (On Demand)
4.5.	Investment Vs Adoption Scenario (On Demand)
4.6.	Analyst Recommendation & Conclusion
Chapter 5.	Global Viral Inactivation Market, by Method 
5.1.	Market Snapshot 
5.2.	Market Performance - Potential Model
5.3.	Viral Inactivation Market, Sub Segment Analysis
5.3.1.	  Solvent Detergent Method
5.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.	   Pasteurization 
5.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 6.	Global Viral Inactivation Market, by Product          
6.1.	Market Snapshot 
6.2.	Market Performance - Potential Model
6.3.	Viral Inactivation Market, Sub Segment Analysis
6.3.1.	   Kits and Reagents
6.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.	    Services
6.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.3.	   Viral Inactivation Systems and Accessories
6.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 7.	Global Viral Inactivation Market, by   Application          
7.1.	Market Snapshot 
7.2.	Market Performance - Potential Model
7.3.	Viral Inactivation Market, Sub Segment Analysis
7.3.1.	    Blood and Blood Products
7.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3.2.	     Cellular and Gene Therapy Products
7.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3.3.	     Stem Cell Products
7.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3.4.	      Tissue & Tissue Products
7.3.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.4.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3.5.	      Vaccine and Therapeutics 
7.3.5.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.5.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 8.	Global Viral Inactivation Market, by    End-User          
8.1.	Market Snapshot 
8.2.	Market Performance - Potential Model
8.3.	Viral Inactivation Market, Sub Segment Analysis
8.3.1.	     Pharmaceutical & Biotechnology Companies
8.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.	      Contract Research Organizations
8.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.	      Academic Research Institutes
8.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 9.	Global Viral Inactivation Market, by Regional Analysis
9.1.	Viral Inactivation Market, Regional Market Snapshot (2016-2026)
9.2.	North America Viral Inactivation Market Snapshot
9.2.1.	U.S.
9.2.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.2.	 Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.2.1.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.2.1.4.	Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.1.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.2.2.	Canada
9.2.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.2.2.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.2.2.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
9.2.2.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.3.	Europe Viral Inactivation Market Snapshot
9.3.1.	U.K. 
9.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.3.1.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.3.1.4.	Application breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.3.1.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.3.2.	Rest of Europe
9.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.3.2.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.3.2.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.3.2.4.	Application breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.3.2.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.	 Asia Viral Inactivation Market Snapshot
9.4.1.	China 
9.4.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.1.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.4.1.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.4.1.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.1.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.2.	India 
9.4.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.4.2.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)
9.4.2.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.2.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.3.	 Japan
9.4.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.3.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.4.3.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.4.3.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.4.3.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.4.4.	Rest of Asia Pacific
9.4.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.4.4.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.4.4.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.4.4.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.4.4.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.5.	Latin America Viral Inactivation Market Snapshot
9.5.1.	Brazil 
9.5.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.1.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.5.1.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.5.1.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.5.1.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   

9.5.2.	Mexico 
9.5.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.5.2.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.5.2.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.5.2.4.	Application  breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.5.2.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
9.6.	Rest of The World 
9.6.1.	Middle East and Africa
9.6.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
9.6.1.2.	Method breakdown estimates & forecasts, 2016-2026 (USD Billion) 
9.6.1.3.	 Product breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.6.1.4.	Application breakdown estimates & forecasts, 2016-2026 (USD Billion)  
9.6.1.5.	End-use breakdown estimates & forecasts, 2016-2026 (USD Billion)   
Chapter 10.	Competitive Intelligence
10.1.	Company Market Share (Subject to Data Availability)
10.2.	Top Market Strategies
10.3.	Company Profiles
10.3.1.	   Clean Cells (France)
10.3.1.1.	Overview
10.3.1.2.	Financial (Subject to Data Availability)
10.3.1.3.	Product Summary
10.3.1.4.	Recent Developments
10.3.2.	 Charles River Laboratories International, Inc. (U.S.)
10.3.3.	Danaher Corporation (U.S.)
10.3.4.	Merck KGAA (Germany
10.3.5.	 Parker Hannifin (U.S.)
10.3.6.	Rad Source Technologies (U.S.)
10.3.7.	Sartorius AG (Germany)
10.3.8.	SGS S.A. (Switzerland)
10.3.9.	Texcell, Inc. (France)
10.3.10.	Viral Inactivated Plasma Systems SA (Switzerland)
Chapter 11.	Research Process
11.1.	Research Process
11.1.1.	Data Mining
11.1.2.	Analysis
11.1.3.	Market Estimation
11.1.4.	Validation
11.1.5.	Publishing
11.1.6.	Research Assumption

Global Viral Inactivation Market valued approximately USD 418.5 million in 2018 is anticipated to grow with a healthy growth rate of more than 14.5% over the forecast period 2019-2026. Global rise in the number of chronic diseases like cancer, diabetes, autoimmune disorders, and other diseases has led to an increase in healthcare expenditure as well as increase in healthcare spending has mainly boosted the market for development of new & enhanced therapies to tackle the rise in these diseases. Increasing R&D innovation, drug discoveries, and FDA approvals leading to commercialization of new drugs has resulted in growth of the market. In addition, growing number of pharmaceuticals companies and investment in the life science sector is also attributable towards the market growth. As Viral inactivation is the vital part in the drug development process. Thus, growing investment in the drug development is prime factor in the market growth. For instance, according to International trade organizations, China is the second largest pharmaceutical market across the globe that is anticipated to value at around $167 billion by the year 2020 with an annual growth rate of about 9.1%. According to the NHMRC and Australian research council awarded about $755 million in grants for promoting research and development projects in life science sector. Similarly, R&D spending in Life Science sector in Australia is estimated to be $630 million per year. Similarly, on December 2017, South Korean government announced to double its funding in pharmaceutical sector to develop new drugs by 2022.
The regional analysis of global Viral Inactivation market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the growing investment in stem cell research coupled with increasing diseases burden. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increase in generics development and manufacturing, ageing population coupled with presence of large number of CROs for clinical research would create lucrative growth prospects for the Viral Inactivation market across Asia-Pacific region.
Major market player included in this report are:
Clean Cells
Charles River Laboratories International, Inc.
Danaher Corporation
Merck KGAA
Parker Hannifin
Rad Source Technologies
Sartorius AG
SGS S.A.
Texcell, Inc.
Viral Inactivated Plasma Systems SA
WuXi PharmaTech (Cayman) Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors& challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Method
Solvent Detergent Method
Pasteurization
By Product
Kits and Reagents
Services
Viral Inactivation Systems and Accessories
by Application
Blood & Blood Products
Cellular & Gene Therapy Products
Stem Cell Products
Tissue & Tissue Products
Vaccines and Therapeutics
by End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic Research Institutes
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Viral Inactivation in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…